Proteomic cancer biomarkers from discovery to approval: It's worth the effort

Danni Li, Daniel W. Chan

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations

Abstract

The current landscape of cancer biomarkers is changing rapidly, with new and exciting developments. With the advances of proteomic technologies, many potential cancer biomarkers have been discovered. However, the number of new cancer biomarkers cleared or approved by the US FDA is rather limited. Although technological advances are important, clearly defining intended use, good study design and appropriate patient specimens are critical for the success of FDA approval. While obtaining FDA clearance/approval for newly developed and clinically useful cancer biomarkers has been slow, the reward for patient care could be enormous.

Original languageEnglish (US)
Pages (from-to)135-136
Number of pages2
JournalExpert Review of Proteomics
Volume11
Issue number2
DOIs
StatePublished - Apr 2014

Keywords

  • IVDMIA
  • OVA1
  • biomarker
  • cancer
  • proteomics

Fingerprint Dive into the research topics of 'Proteomic cancer biomarkers from discovery to approval: It's worth the effort'. Together they form a unique fingerprint.

Cite this